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Background: Oncolytic adenoviruses are promising as anticancer agents but have limited clinical responses. Our
previous study showed that heat shock transcription factor 1 (HSF1) overexpression could increase the anti-tumor
efficacy of E1B55kD deleted oncolytic adenovirus through increasing the viral burst. Due to the important roles of
heat shock proteins (HSPs) in eliciting innate and adaptive immunity, we reasoned that besides increasing the viral
burst, HSF1 may also play a role in increasing tumor specific immune response.
Methods: In the present study, intra-dermal murine models of melanoma (B16) and colorectal carcinoma (CT26)
were treated with E1B55kD deleted oncolytic adenovirus Adel55 or Adel55 incorporated with cHSF1, HSF1i, HSP70,
or HSP90 by intra-tumoral injection. Tumors were surgically excised 72 h post injection and animals were analyzed
for tumor resistance and survival rate.
Results: Approximately 95% of animals in the Adel55-cHSF1 treated group showed sustained resistance upon
re-challenge with autologous tumor cells, but not in PBS, Adel55, or Adel55-HSF1i treated groups. Only 50–65%
animals in the Adel55-HSP70 and Adel55-HSP90 treated group showed tumor resistance. Tumor resistance was
associated with development of tumor type specific cellular immune responses. Adel55-cHSF1 treatment also
showed higher efficacy in diminishing progression of the secondary tumor focus than Adel55-HSP70 or Adel55-
HSP90 treatment.
Conclusions: Besides by increasing its burst in tumor cells, cHSF1 could also augment the potential of E1B55kD
deleted oncolytic adenovirus by increasing the tumor-specific immune response, which is beneficial to prevent
tumor recurrence. cHSF1 is a better gene for neoadjuvant immunotherapy than other heat shock protein genes.
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Malignant tumors are of a highly complex nature, a cure
will probably result only from complete eradication of
all of the tumor cells. Current modalities for cancer ther-
apy are not selective and may have severe adverse
effects. Oncolytic adenoviruses are a class of promising* Correspondence: tcmhuangx59@163.com
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reproduction in any medium, provided the oranticancer agents, which are designed to selectively rep-
licate in tumor cells and lead to cancer-specific cytotox-
icity [1,2]. However, clinical experiences show that these
agents alone failed to generate sustained clinical
responses or to cause complete tumor regressions [3].
Our previous study showed that constitutively active
heat shock transcription factor 1 (cHSF1) expression
could dramatically increase the replication of the replica-
tion competent adenovirus Adel55 in tumor cells and
enhance the antitumor efficacy of Adel55 in vitro and
in vivo [4]. Increasing evidence indicates that heat shock. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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portant roles in eliciting innate and adaptive immunity
[5-7]. We reasoned that besides increasing the viral
burst, cHSF1 may also play a role in increasing tumor
specific immune response.
The ability of HSPs to chaperone peptides and to pro-
mote T-cell responses by activating dendritic cells (DCs)
seems to be the common feature associated with all the
major HSPs, including HSP110, gp96, HSP90, and
HSP70 [8-11]. When peptide-loaded HSPs are released
from the cells, they bind to antigen-presenting cells
(APCs) mainly through the CD91 receptor (a2-macro-
globulin receptor), CD40 and LOX-1. Once taken up by
APCs, the peptides are translocated to MHC class-I
molecules, which traffic to the cell surface enabling effi-
cient presentation to CD8+ T cells, a vital step in raising
a systemic antitumor response. Generating antitumor
immune responses against tumor-associated self-
antigens and mutated antigens requires endogenous
nonmicrobial danger molecules that activate APCs. Be-
sides their ability to chaperone antigenic peptides, HSPs
may function as endogenous nonmicrobial danger mole-
cules [12-14] that can up-regulate the expression of cost-
imulatory and antigen-presenting molecules on DCs.
They also stimulate the secretion of proinflammatory
cytokines such as interleukin 12 (IL-12), leading to the
activation of natural killer (NK) cells and other immune
cells [15]. Tumor-derived HSPs provide effective tumor
vaccines in mouse models [16-18], and the ability of
human melanoma-derived HSP70 to stimulate autolo-
gous melanoma-specific T cells also has been shown
in vitro [19].
Based on these evidences, we hypothesized that cHSF1
overexpression could achieve more potent tumor im-
munogenicity than any HSP alone due to its ability to
increase various HSPs expression at the same time. We
evaluated the effect of enhanced tumor immunogenicity
by direct intra-tumoral injection of Adel55-cHSF1 or
control viruses prior to surgical excision of intra-dermal
murine tumors to result in measurable anti-tumor im-
mune responses. We further evaluated the ability of
Adel55-cHSF1 to alter growth of alternative tumor foci
and on survival of animals.
Materials and methods
Plasmids
The E1B55kD gene deleted oncolytic adenovirus vector
pAdel55 was established by nested PCR using pXC1
(Microbix Biosystems, Ontario, Canada) as the template.
The viral region comprising nucleotides 1318–2038 was
amplified using a primer set of 5 GCC GAC ATC ACC
TGT GTC TAG AGA ATG -3′ (L1) and 5′- TCA GAT
GGG TTT CTT CAC TCC ATT TAT CCT-3′ (R1). The
region containing nucleotides 2005–2266 was amplifiedwith another primer set of 5′-ATA AAG GAT AAA
TGG AGT GAA GAA ACC CAT CTG AG-3′ (L2) and
5′-GAA GAT CTA TAC AGT TAA GCC ACC TAT
ACA ACA-3′ (R2). Using the mixture of the two PCR
products as template, a 955 bp fragment was then ampli-
fied using primers L1 and R2. This fragment was cut by
Xba I and Bgl II and cloned into pXC1 to generate the
plasmid pXC1-del55. SV40 polyA (160 bp) were
obtained by PCR using pcDNA3 (invitrogen) as template
and two primers: 5′-TGT GGA TCC TCT AGA GCT
CGC TGA-3′ and 5′-TCT AGA TCT CGA GCC CCA
GCT GGT-3′. Then it was digested with BamH I and
Bgl II and cloned into the Bgl II site of pXC1- del55 to
generate the plasmid pAdel55. The correct construction
of this vector was confirmed by DNA sequencing. Con-
stitutively active heat shock transcription factor 1
(cHSF1) and HSF1 miRNA inhibitor (HSF1i) gene were
made as described previously [4]. First, cHSF1, HSF1i,
HSP70 or HSP90 gene was cloned into the polycloning
site of shuttle vector pCA13 (Microbix Biosystems, On-
tario, Canada). Then the whole gene expression cassette
containing CMV promoter, transgene and SV40 polyA
site was cut from pCA13-cHSF1, pCA13-HSF1i, pCA13-
HSP70 or pCA13-HSP90 by Bgl II and subcloned into
the corresponding site of pAdel55 to generate pAdel55-
cHSF1, pAdel55-HSF1i, pAdel55-HSP70 or pAdel55-
HSP90.
Virus construction
Adenovirus was generated by standard homologous re-
combination techniques using the plasmid pAdel55,
pAdel55-cHSF1, pAdel55-HSF1i, pAdel55-HSP70 or
pAdel55-HSP90 and the adenovirus packaging plasmid
pBHGE3 (adenovirus packaging plasmid, Microbix Bio-
systems, Ontario, Canada) in HEK293 cells. Recombin-
ant adenovirus plaque purified, propagated on HEK293
cells and purified by CsCl gradient according to standard
techniques. Particle titers of all adenoviruses were deter-
mined by absorbance measurements at 260 nm, and
functional plaque formation unit (pfu) titers were deter-
mined by plaque assay on HEK293 cells. The titer of
stocks was 2.3 × 1011 pfu/ml for Adel55 (bioactivity 25.1),
5.1 × 1011 pfu/ml (bioactivity 23.5) for Adel55-cHSF1,
3.9 × 1011 pfu/ml (bioactivity 22.8) for Adel55-HSF1i,
2.9 × 1011 pfu/ml (bioactivity 23.3) for Adel55-HSP70,
and 4.1 × 1011 pfu/ml (bioactivity 24.3) for Adel55-
HSP90.
Cell lines and culture
C57B/6 mouse origin (H-2b) melanoma cell line B16
and Balb/C origin (H-2D) colorectal tumor cell line
CT26 were obtained from American Type Tissue Collec-
tion (ATCC, Rockville, MD, USA). Cells were kept at 37
degree, 5% CO2 and 95% humidity in Dulbecco’s
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supplemented with 10% (v/v) heat inactivated fetal bo-
vine serum (Invitrogen, Carlsbad, CA, USA), 2 mM L-
glutamine and 100 units/ml penicillin and 1,000 μg/ml
streptomycin (Invitrogen, Carlsbad, CA, USA).
Animal experiments
All animal experiments were carried out in accordance
with the National Institute of Health Guide for the Care
and Use of Laboratory Animals. Five-week-old female
C57B/6 or Balb/C mice were injected intradermally with
1 × 106 B16 or CT26 cells in a total volume of 50 μl by
aseptic technique on the murine dorsum after shaving in
sterile phosphate buffered saline. Tumor growth was
measured with calipers. The perpendicular tumor diam-
eter was measured every 5 days and tumor volume (V)
was calculated by the formula for a rotational ellipsoid:
V (mm3) = length ×width2/2. In our multifocal tumor
model, an initial inoculum was given on the left dorsum.
On day 5, a secondary inoculum of tumor cells was
transplanted on the opposite flank.
Animals were injected with 5 × 108 pfu Adel55, Adel55-
cHSF1, Adel55-HSF1i, Adel55-HSP70, Adel55-HSP90 or
phosphate buffered saline once a day for 2 consecutive
days. Tumors were surgically excised 72 h later with small
margins and the skin sutured using 3.0 nylon.
CTL assay
Cytotoxicity was assessed by the ability of spleen effector
cells to lyse various tumor target cells. Splenocytes were
derived by mechanical disruption of spleens under asep-
tic conditions in PBS. Red blood cells were removed by
5-min incubation in ammonium chloride lysis buffer
(Pharmingen). Splenocytes were stimulated for 6 days in
24-well tissue culture plates at a ratio of 150:1 with
25 μg/ml mitomycin C-treated homolog cells in RPMI
medium containing 10% fetal calf serum (RPMI-10%
FCS) supplemented with 1 ng/ml recombinant murine
IL-2 (BD Biosciences). Splenocytes were harvested from
plates by Ficoll density centrifugation and added to 96-
well U-bottom plates (Corning) in RPMI- 10% FCS. Tar-
get cells were harvested, washed in PBS and labeled with
200 uCi of 51Cr (Na2CrO4 in sterile saline; Amersham
Biochemicals) in DMEM-10% FCS supplemented with
50 μM 2-mercaptoethanol for 90 min. Target cells were
washed three times with ten times the volume of PBS
and then added to plates containing splenocytes at the
ratios described in the figure legends. After 4 h incuba-
tion at 37 degree, 5% CO2, the plates were harvested
using a Skatron Harvesting System (Skatron). Chromium
release into supernatant was counted using an ICN
gamma counter. Spontaneous Cr leakage was measured
by six wells that did not contain splenic effector cells.
Maximum Cr leakage was determined by addition ofTriton X-100 to a final concentration of 0.8% to six
wells. Corrected % lysis was determined by the following
formula: Corrected lysis = 100 × (effector cell sample
chromium release - spontaneous target chromium
released)/(maximum target chromium released - spon-
taneous target chromium released).
Statistical analysis
Data are expressed as means± SD values. Student’s t test
was applied to study the relationship between the different
variables. Statistical significance was taken at P< 0.05.
Tumor resistance statistics was determined by Fisher exact
analysis. Survival analysis was performed using the
Kaplan-Meier test.
Results
Intratumor injection of Adel55-cHSF1 prevents the
growth of Secondary Tumor
On the basis of our previous study, we applied Adel55-
cHSF1 for tumor gene therapy in immune-competent
mice. It has been reported that HSPs overexpression
could increase the tumor specific immune response
[8-11]. Since we overexpressed cHSF1 by using Adel55-
cHSF1, we reasoned that Adel55-cHSF1 might also be
able to increase the immune response. C57B/6 or Balb/C
mice were injected intradermally with 1 × 106 B16 or
CT26 cells, and then mice with approximately 100 mm3
B16 or CT26 tumors growing subcutaneously were trea-
ted by intratumoral administration of 5 × 108 pfu differ-
ent recombinant adenoviruses or vehicle control once a
day for 2 consecutive days, and then surgically excised
the tumor after 72 h. Animals were given a 2-week recov-
ery period and then injected on the opposite dorsal sur-
face with autologous tumor cells. Positive tumor
formation was determined by at least minimal, palpable
tumor 2 weeks from the time of tumor injection.
We show in Table 1 the number of animals resistant
to tumor formation in the various treatment groups. Of
note, no animals had recurrent tumor formation at the
initial surgical site. Although tumor resistance was
observed in the Adel55-cHSF1, Adel55-HSP70 and
Adel55-HSP90 treatment group, Adel55-cHSF1 was the
most effective one with 95% animals resistant to tumor
re-innoculation, while Adel55-HSP70 or Adel55-HSP90
only resulted in 50–65% animals free of tumors (P< 0.05,
Adel55-cHSF1 vs. Adel55-HSP70 or Adel55-HSP90). No
tumor resistance was detected in the PBS, Adel55 or
Adel55-HSF1i injected groups. Similar results were got
from both B16 and CT26 groups.
Adel55-cHSF1 can induce tumor type specific cytotoxic
T lymphocyte activity when splenocytes are stimulated
in vitro
Next, we determined the immunological basis of tumor
resistance in these animals. In previous experiments,
Table 1 Number of animals resistant to tumor formation after treatment
PBS Adel55 Adel55-cHSF1 Adel55-HSF1i Adel55-HSP70 Adel55-HSP90
B16 0/21 0/19 20/21* 0/21 12/21 11/21
CT26 0/22 0/17 24/25* 0/23 15/23 14/23
Mice with approximately 100 mm3 B16 or CT26 tumors growing subcutaneously were treated by intratumoral administration of 5 × 108 pfu agents in the top
column once a day for 2 consecutive days. Tumors were excised after 72 h and animals were re-inoculated with autologous tumor cells 2 weeks after surgery.
Positive tumor formation was determined by at least minimal, palpable tumor 2 weeks from the time of tumor injection. Untreated animals as a positive control
were injected and showed tumor formation. *represent statistical significance (P< 0.05, Adel55-cHSF1 vs. Adel55-HSP70 or Adel55-HSP90).
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can confer tumor immunity to the various cell lines uti-
lized [20-22]. Established subcutaneously tumors were
treated by intratumoral injection of PBS, Adel55,
Adel55-cHSF1 or Adel55-HSF1i. Splenocytes from re-
sistant and non-resistant animals were obtained two
weeks after the second tumor challenge. Spleen cells
were restimulated with mitomycin C-treated homolog
cells to get effector cells. The effector cells were then
assayed for cytolytic function by using B16 or CT26 cells
as targets. As shown in Figure 1, B16 tumor resistant
animals had developed B16 specific cellular immune
responses (Figure 1A and 1B), and CT26 tumor resistant
animals had developed CT26 specific cellular immune
responses (Figure 1C and 1D). In contrast, animals
injected with PBS, Adel55, or Adel55-HSF1i showed lack
of cell specific cellular immunity. This indicates that
Adel55-cHSF1 can induce tumor type specific cytotoxic
T lymphocyte activity when splenocytes are stimulated
in vitro. Results were similar from splenocytes of
Adel55-HSP70 or Adel55-HSP90 treated animals which
is consistant with the previous studies (data not shown).
This experiment indicates that cHSF1 delivery can lead
to tumor resistance due to induction of tumor type spe-
cific cytotoxic T lymphocyte.
To detect what type of cytotoxic T cells induced by
Adel55-cHSF1, cytotoxic T lymphocyte assays with
blocking antibodies was performed. As shown in Fig-
ure 2, only when anti-CD8 antibody was added, the
tumor type specific cytotoxic T lymphocyte activity
could be inhibited. It indicates that these types of T cells
are CD8 type.Adel55-cHSF1 can increase the overall survival of animals
re-inoculated with secondary tumors
Next we addressed the effect of Adel55-cHSF1 neoadju-
vant therapy on overall survival of animals. In our ex-
perience, surgical excision of tumors less than 200 mm3
did not result in metastasis or affect survival. Local or
distant tumor relapse was not observed after surgical ex-
cision of primary tumors in any of the models studied.
Overall survival of animals after neoadjuvant adenovirus
therapy is shown in Figure 3, for the B16 (Figure 3A, B,
C) and CT26 (Figure 3D, E, F) tumor models, respect-
ively. Data shown are from three independentexperiments. We observed a long-term survival rate in
the Adel55-cHSF1-treated group, whereas no mouse
survived in the PBS-, Adel55- or Adel55-HSF1i-treated
groups at the end of the experiments (P< 0.05). In
Figure 3D, one mouse treated with Adel55-cHSF1 died
at 1 week due to unknown illness, with no palpable
tumor formation, while in Figure 3E and F, no mice trea-
ted with Adel55-cHSF1 died until around two to three
weeks, which made the long term survival rate in
Figure 3D less than in the other two experiments. We
didn’t find correlation between the illness and the
Adel55-cHSF1 injection.
In both tumor models, survival advantage is associated
with Adel55-cHSF1 treatment. PBS, Adel55 or Adel55-
HSF1i intratumor injections prior to surgical excision
did not confer any protection against secondary tumor
challenge or prolongation of survival. All animals which
formed persistent tumors upon re-inoculation of tumor
cells eventually died. In the Adel55-cHSF1 group, some
animals did form palpable tumors by day 7 which subse-
quently regressed. These animals remained tumor free
for the duration of the study. The survival benefit asso-
ciated with Adel55-cHSF1 treatment might be related to
development of anti-cellular immunity as described
above. Both B16 and CT26 are aggressive tumors and no
late regressions were observed.Adel55-cHSF1 can prevent micrometastases of tumors
and is superior to Adel55-HSP70 or Adel55-HSP90
Tumor relapse is one of the difficulties with surgical
therapy for many different tumors, which is believed to
be a consequence of micrometastatic tumor not previ-
ously detected. Previous studies demonstrated that HSP
gene delivery could prevent the tumor micrometastases.
To compare the effect of cHSF1 with HSP gene, we treat
C57B/6 or Balb/C mice with multifocal B16 or CT26
tumor which is clinically applicable model of microme-
tastases. Only a single tumor focus was treated with
PBS, Adel55, Adel55-cHSF1, Adel55-HSP70, Adel55-
HSP90 or Adel55-HSF1i. The treated tumor focus was
surgically removed and tumor growth of the tumor focus
on the opposite flank was assessed. In Figure 4, we show
tumor growth curve of B16 (Figure 4A) or CT26
(Figure 4B) tumors over time, and the picture of the op-
posite flank of different group of mice bearing B16 or
Figure 1 Tumor type specific cytotoxic T lymphocyte activity induced by Adel55-cHSF1 administration. Established subcutaneously B16
tumors were treated by intratumoral injection of PBS, or 5 × 108 pfu Adel55, Adel55-cHSF1 or Adel55-HSF1i. Splenocytes from resistant and
non-resistant animals were obtained two weeks after the second tumor challenge and restimulated with mitomycin C-treated B16 cells as
effector cells. The effector cells were then assayed for cytolytic function by using B16 (A) or CT26 (B) cells as targets. The ratio 25, 50 and 100 of
effector/target cells were detected. Percent specific lysis of target cells is depicted on the y-axis. All results are shown as mean± SD (n = 5).
Similarly, established subcutaneously CT26 tumors were treated by intratumoral injection of PBS, or 5 × 108 pfu Adel55, Adel55-cHSF1 or
Adel55-HSF1i. Splenocytes from resistant and non-resistant animals were obtained two weeks after the second tumor challenge and restimulated
with mitomycin C-treated CT26 cells as effector cells. The effector cells were then assayed for cytolytic function by using CT26 (C) or B16 (D) cells
as targets.
Figure 2 Cytotoxic T lymphocyte assays with blocking
antibodies. Percent specific lysis of target cells is depicted on the y-
axis. Pooled splenocytes from two animals resistant to autologous
tumor challenge from the treatment groups identified on the x-axis
at an effector to target ratio 100:1. Anti-CD4 or anti-CD8 antibodies
(Pharmingen) were added at 30 μL/well to inhibit activity. The data
represent the mean± SD of three determinations.
Fan et al. Journal of Translational Medicine 2012, 10:101 Page 5 of 8
http://www.translational-medicine.com/content/10/1/101CT26 tumors at day 30 (Figure 4C, one mouse was
chosen randomly from each group). It shows that
Adel55-cHSF1 treatment of a single focus of multifocal
tumors dramatically decreased tumor growth velocity of
the secondary focus, and the growth is much slower
than Adel55-HSP70 and Adel55-HSP90 treated group.
However, PBS, Adel55 and Adel55-HSF1i treatment did
not show such effect. It indicates that cHSF1 is a super-
ior gene for neoadjuvant immunotherapy of various
tumors.
Discussion
Neoadjuvant immunotherapy is very important to pre-
vent tumor relapse when the primary treatment method
is surgical resection. Heat shock proteins are molecular
chaperones previously identified to be the component of
high molecular weight tumor cell lysate that conferred
tumor immunity with tumor cells [23]. HSPs have the
capability of binding antigenic peptides and presenting
to antigen presenting cells to result in anti-tumor cellu-
lar immune responses [16]. Additionally, HSPs have
been shown to activate antigen presenting cells to aug-
ment generation of immune responses [24]. Tumors
engineered to overexpress HSPs have altered
Figure 3 Kaplan–Meier survival analysis of mice after re-challenging with autologous tumor. C57B/6 or Balb/C mice with approximately
100 mm3 B16 (A, B, C) or CT26 tumors (D, E, F) growing subcutaneously were treated by intratumoral administration of 5 × 108 pfu of PBS,
Adel55, Adel55-cHSF1 or Adel55-HSF1i once a day for 2 consecutive days. Tumors were excised after 72 h. Animals were re-inoculated with
autologous tumor cells subcutaneously 2 weeks after surgery and followed for survival. Criteria for removal of animals from consideration
included weight loss> 12%, inability to ambulate, inability to feed, or loss of normal grooming. Data shown are from three independent
experiments for both tumor models (n = 4-6 for all groups). (*) denotes statistical significance (Adel55-cHSF1 vs. PBS or Adel55 or Adel55-HSF1i).
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[25]. In animal models, purified HSP-antigen complexes
for vaccination have resulted in sustained anti-tumor
immune responses against autologous tumor cells [26].
However, the immunity generated by the heat shock
proteins, such as HSP70 or HSP90 was limited and only
fifty percent of the mice treated could resist the second-
ary tumor challenge [27]. Consistent with these studies,
our data also showed only 50–65% animals in the
Adel55-HSP70 and Adel55-HSP90 treated group showed
tumor resistance. To find a better gene and delivery
method for enhanced neoadjuvant immunotherapy, we
employed the oncolytic adenovirus vector to deliver con-
stitutively active HSF1 gene. Our previous study showed
cHSF1 delivery could eradicate tumor growth by in-
creasing the oncolytic effect and replication of oncolytic
adenovirus Adel55. We reasoned that the replication
property of Adel55-cHSF1 could lead to higher gene ex-
pression than regular adenoviral vector and cHSF1 itself
could lead to various heat shock protein gene expres-
sion, both of which are ideal for better cancer
immunotherapy.In our study, we used B16 and CT26 murine cancer
cell line which are poorly immunogenic and tumor cell
vaccination is incapable of generating anti-tumor im-
munity. We found that direct intra-tumor Adel55-
cHSF1 injection prior to surgical resection had the cap-
ability of generating subsequent tumor resistance in 95%
mice, which is much more advantageous than Adel55-
HSP70 or Adel55-HSP90 injection. Cellular immune
responses phenotypes were CD8+ T-cell mediated,
which are consistent with reports in the literature in the
murine tumor models. Interestingly, CTL reactivity was
only detected in those mice treated with Adel55-cHSF1.
No measurable CTL activity could be detected in PBS,
Adel55 or Adel55-HSF1i treated groups. Adel55-cHSF1
was also effective in altering growth of distant tumor. In
a model system with multiple tumor foci, animals with
surgical resection of a single tumor focus injected with
Adel55-cHSF1 continued to have immune responses and
prevent the secondary tumor growth, and the velocity of
tumor growth is much faster in Adel55-HSP70 and
Adel55-HSP90 treated groups. It suggests Adel55-cHSF1
may be an effective strategy for the treatment of tumors












Figure 4 Effect of neoadjuvant immuno-gene therapy on distant tumor growth. (A) Mice were inoculated with tumor cells on one flank
and 5 days later on the opposite flank. The perpendicular tumor diameter was measured every 5 days, and tumor volume (V) was calculated by
the formula for a rotational ellipsoid: V (mm3) = length×width2/2. When the opposite tumor foci reached 50 mm3, the larger tumor was injected
with PBS, 5 × 108 pfu Adel55, Adel55-cHSF1, Adel55-HSF1i, Adel55-HSP70 or Adel55-HSP90 and surgically excised 72 h post injection. The
progression of the opposite tumor foci was measured for one month. (A) C57B/6 mice inoculated with B16 tumor cells (n = 8). (B) Balb/C mice
inoculated with CT26 tumor cells (n = 8). *represent statistical significance (P< 0.05, Adel55-cHSF1 vs. Adel55-HSP70 or Adel55-HSP90). (C) The
picture shows the opposite tumor foci of different groups of Balb/C or C57B/6 mice bearing B16 or CT26 tumors and tumors dissected at day 30.
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static disease.
In our system, Adel55-cHSF1 was both oncolytic and
superior in generation of anti-tumor immune responses.
This virus has the capability of replicating in tumor cells,
resulting in tumor cell death, in addition to cHSF1 ex-
pression allowing for various HSP overexpression and
liberation of HSP-antigen complexes for immune system
recognition. cHSF1 gene transfer is not dependent on
knowledge of the tumor-specific antigen and should becapable of generating tumor-specific immune responses
against most immunogenic solid tumors.Conclusions
Our results suggest that the advantage of oncolytic
adenoviral vector, Adel55-cHSF1 for tumor gene therapy
includes the enhanced oncolytic adenovirus replication
and induction of tumor-specific immune response. It
has the potent for the combined application of heat
Fan et al. Journal of Translational Medicine 2012, 10:101 Page 8 of 8
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ment in the future.
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